Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma

Cancer

Volumn 104, Issue 9, 2005, Pages 1825-1833

  Kim, Jin Seuk ^a   Han, Joungho ^b   Shim, Young Mog ^b   Park, Joobae ^a,b   Kim, Duk Hwan ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

H cadherin; Methylation; Nonsmall cell lung carcinoma; Progression; Survival

Indexed keywords

CADHERIN; H CADHERIN; KI 67 ANTIGEN; MOLECULAR MARKER; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL ERROR; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; STATISTICAL ANALYSIS; TUMOR GROWTH;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 27244444605     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21409     Document Type: Review

References (23)

1. Idhe DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434-1441.
2. Marcus PM. Lung cancer screening: an update. J Clin Oncol. 2001;19:83S-86S.
3. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251:1451-1455.
4. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5:806-811.
5. Behrens J. The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat. 1994;24:175-184.
6. Takeuchi T, Ohtsuki Y. Recent progress in T-cadherin (CDH13, H-cadherin) research. Histol Histopathol. 2001;16:1287-1293.
7. Lee SW. H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med. 1996;2:776-782.
8. Lee SW, Reimer CL, Campbell DB, Cheresh P, Duda RB, Kocher O. H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo. Carcinogenesis. 1998;19:1157-1159.
9. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet. 1998;103:96-101.
10. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001;61:4556-4560.
11. Zhong Y, Delgado Y, Gomez J, Lee SW, Perez-Soler R. Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity. Clin Cancer Res. 2001;7:1683-1687.
12. Toyooka S, Maruyama R, Toyooka KO, et al. Smoker exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 2003;103:153-160.
13. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
14. Toyooka KO, Toyooka S, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Therapeutics. 2001;1:61-67.
15. Hanabata T, Tsukuda K, Toyooka S, et al. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep. 2004;12:177-180.
16. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249-255.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specrfic PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
18. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small cell lung cancer. J Clin Oncol. 2004;22:2363-2370.
19. Sulzer MA, Leers MP, van Noord JA, Bollen ECM, Theunissen PHMH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med. 1998;157:1319-1323.
20. CIP1/WAF1 expression. Mol Cell Biol. 2003;23:566-578.
21. Zhong Y, Lopez-Barcons L, Haigentz M, Ling YH, Perez-Soler R. Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression. Int J Oncol. 2004;24:1573-1579.
22. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF. Hypermethylation of FHIT as a prognostic marker in non-small cell lung carcinoma. Cancer. 2004;100:1472-1477.
23. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer. 2004;91:771-774.